Kiniksa Pharmaceuticals

  • TickerKNSA
  • ISINBMG5269C1010
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
David Nierengarten
  • David Nierengarten
 PRESS RELEASE
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global...

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 9:40 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at . A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference. About KiniksaKiniksa is a biopharmaceutical company...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) f...

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis –- ARCALYST now available on prescription basis in the U.S. –- Kiniksa One Connect™ program provides ongoing patient access and support services – HAMILTON, Bermuda, April 01, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that ARCALYST ® (rilonacept), a weekly, su...

 PRESS RELEASE
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericardit...

Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis Registry will continue to advance the understanding of the clinical outcomes and management of recurrent pericarditis in partnership with the healthcare community, patients and patient advocates HAMILTON, Bermuda, March 02, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the official launch of the RESONANCE registry in pediatric and adult patients with recurrent peri...

 PRESS RELEASE
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global...

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 9:40 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at . A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference. About KiniksaKiniksa is a biopharmaceutical company...

 PRESS RELEASE
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) f...

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis –- ARCALYST now available on prescription basis in the U.S. –- Kiniksa One Connect™ program provides ongoing patient access and support services – HAMILTON, Bermuda, April 01, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that ARCALYST ® (rilonacept), a weekly, su...

 PRESS RELEASE
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericardit...

Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis Registry will continue to advance the understanding of the clinical outcomes and management of recurrent pericarditis in partnership with the healthcare community, patients and patient advocates HAMILTON, Bermuda, March 02, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the official launch of the RESONANCE registry in pediatric and adult patients with recurrent peri...

 PRESS RELEASE
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results an...

Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity - Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 -- Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal date of March 21, 2021 -- Clinical data expected in 1H 2021 from KPL-404 (anti-CD40) Phase 1 clinical trial and mavrilimumab Phase 2 clinical trial in severe COVID-19 -- Year-end 2020 cash reserves of approximately $323 million - HAMILTON, Bermuda, Feb. 23, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: K...

 PRESS RELEASE
KNSA Kiniksa Pharmac... (Health Care)

Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones

Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones - PDUFA goal date of March 21, 2021 for rilonacept in recurrent pericarditis -- Data from Phase 2 portion of mavrilimumab Phase 2/3 trial in severe COVID-19 pneumonia and hyperinflammation expected in 1H 2021 -- Final Phase 1 KPL-404 data expected in 1H 2021 - HAMILTON, Bermuda, Jan. 11, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today highlighted its corporate priorities and expected...

David Nierengarten
  • David Nierengarten
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus

ResearchPool Subscriptions

Get the most out of your insights

Get in touch